Pharmaceutical Stocks To Research - November 4th

Key Points

• MarketBeat’s pharmaceutical-stock screener highlighted seven names: Eli Lilly, Johnson & Johnson, AbbVie, Pfizer, Novo Nordisk, Gilead Sciences, and Abbott Laboratories, based on their recent dollar trading volume.
• All seven stocks were reported higher in Wednesday trading. Gilead rose $6.92 to $174.39, while Eli Lilly gained $11.80 to $1,421.18.
• The companies cover a broad range of medicines and healthcare businesses; the article notes that investors face risks including clinical-trial outcomes, regulatory decisions, patent expirations, and healthcare-policy changes.

Eli Lilly and Company, Johnson & Johnson, AbbVie, Pfizer, Novo Nordisk A/S, Gilead Sciences, and Abbott Laboratories are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies involved in researching, developing, manufacturing, or selling prescription and over-the-counter medicines. For investors, these stocks can offer growth potential from successful drug launches and strong demand, but they may also carry risks related to clinical-trial results, regulatory approvals, patent expirations, and healthcare policy changes. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of LLY traded up $11.80 during midday trading on Wednesday, hitting $1,421.18. The company had a trading volume of 1,579,815 shares, compared to its average volume of 2,940,887. The stock has a market cap of $1.34 trillion, a price-to-earnings ratio of 46.22, a PEG ratio of 1.77 and a beta of 0.40. The company's 50 day moving average price is $1,204.03 and its 200 day moving average price is $1,095.92. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,449.68.

Read Our Latest Research Report on LLY

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Shares of JNJ stock traded up $7.92 during trading hours on Wednesday, hitting $274.09. 4,183,575 shares of the company were exchanged, compared to its average volume of 7,937,097. The stock has a market capitalization of $659.83 billion, a price-to-earnings ratio of 41.56, a P/E/G ratio of 2.67 and a beta of 0.22. Johnson & Johnson has a one year low of $185.12 and a one year high of $282.02. The business's 50-day simple moving average is $265.60 and its two-hundred day simple moving average is $247.46. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02.

Read Our Latest Research Report on JNJ

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

NYSE ABBV traded up $5.03 on Wednesday, hitting $291.02. 3,186,899 shares of the stock traded hands, compared to its average volume of 6,321,796. The stock has a 50-day moving average of $270.23 and a 200 day moving average of $237.89. AbbVie has a twelve month low of $190.75 and a twelve month high of $298.74. The company has a market capitalization of $514.18 billion, a P/E ratio of 50.14, a price-to-earnings-growth ratio of 1.31 and a beta of 0.20.

Read Our Latest Research Report on ABBV

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Shares of NYSE PFE traded up $0.59 during trading on Wednesday, reaching $30.59. The stock had a trading volume of 23,360,228 shares, compared to its average volume of 39,702,828. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock has a market cap of $174.35 billion, a PE ratio of 40.30, a P/E/G ratio of 2.08 and a beta of 0.31. Pfizer has a one year low of $23.62 and a one year high of $31.06. The firm's 50 day moving average price is $28.64 and its two-hundred day moving average price is $26.84.

Read Our Latest Research Report on PFE

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Novo Nordisk A/S stock traded up $2.78 during mid-day trading on Wednesday, reaching $42.97. The company's stock had a trading volume of 15,884,853 shares, compared to its average volume of 16,412,580. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The business has a 50 day moving average price of $40.97 and a 200-day moving average price of $44.15. The firm has a market cap of $191.85 billion, a price-to-earnings ratio of 10.50, a PEG ratio of 1.37 and a beta of 0.70.

Read Our Latest Research Report on NVO

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Shares of Gilead Sciences stock traded up $6.92 during trading hours on Wednesday, reaching $174.39. The company's stock had a trading volume of 3,853,415 shares, compared to its average volume of 6,810,903. The company's 50 day simple moving average is $151.77 and its 200 day simple moving average is $140.25. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38. Gilead Sciences has a one year low of $116.88 and a one year high of $175.65. The stock has a market cap of $216.31 billion, a P/E ratio of -55.19 and a beta of 0.35.

Read Our Latest Research Report on GILD

Abbott Laboratories (ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Shares of ABT traded up $6.00 during midday trading on Wednesday, hitting $115.40. 5,501,172 shares of the stock traded hands, compared to its average volume of 11,166,326. The business's 50 day moving average price is $104.09 and its two-hundred day moving average price is $101.91. The firm has a market capitalization of $199.68 billion, a PE ratio of 43.03, a price-to-earnings-growth ratio of 1.93 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $132.02.

Read Our Latest Research Report on ABT

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.